We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Impact of Nebivolol on Central Aortic Pressure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01051947
Recruitment Status : Withdrawn (Similar study already published)
First Posted : January 20, 2010
Last Update Posted : August 1, 2011
Information provided by:

Study Description
Brief Summary:
A randomized, cross-over, single-blind study to compare the effects of nebivolol and metoprolol on central aortic pressure and peripheral brachial pressure in patients with stable cardiovascular disease.

Condition or disease Intervention/treatment
Central Aortic Pressure Drug: Nebivolol Drug: Metoprolol

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: Impact of Nebivolol on Central Aortic Pressure
Study Start Date : December 2009
Primary Completion Date : May 2010
Study Completion Date : May 2010

Arms and Interventions

Arm Intervention/treatment
Experimental: Nebivolol
Nebivolol therapy for 2-6 weeks depending on blood pressure readings
Drug: Nebivolol
10 mg by mouth daily for 2 weeks 20 mg by mouth daily for 2 weeks 40 mg by mouth daily for 2 weeks
Experimental: Metoprolol
Metoprolol therapy for 2-6 weeks depending on blood pressure readings
Drug: Metoprolol
dosage prescribed prior to starting on study

Outcome Measures

Primary Outcome Measures :
  1. Stable blood pressure [ Time Frame: 6 months ]
    Subjects will be randomized to nebivolol or metoprolol. Their medication will be titrated so that their blood pressure is within 10% of their initial reading.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   45 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects with history of hypertension
  • Subjects who have received metoprolol for a minimum of 3 months

Exclusion Criteria:

  • Patients who have had an acute myocardial infarction, coronary revascularization or who have been hospitalized for heart failure or cardiac arrhythmia in the past 6 months
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01051947

United States, Nebraska
The Cardiac Center at Creighton University
Omaha, Nebraska, United States, 68131
Sponsors and Collaborators
Creighton University
Principal Investigator: Jennifer Campbell, PharmD Creighton University
More Information

Responsible Party: Jennifer Campbell, PharmD, Creighton University
ClinicalTrials.gov Identifier: NCT01051947     History of Changes
Other Study ID Numbers: 08-15168
First Posted: January 20, 2010    Key Record Dates
Last Update Posted: August 1, 2011
Last Verified: July 2011

Keywords provided by Creighton University:
central aortic pressure

Additional relevant MeSH terms:
Anti-Arrhythmia Agents
Antihypertensive Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Adrenergic beta-1 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists